After falling nearly 20% from their 52-week high, the stock has since rebounded, climbing roughly 20% from its 52-week low—a move that traditionally signals the entry into a new bull market.

Brazilian pulp and paper maker Suzano will hold a majority stake in a new venture.

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=151715&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=151716&wire=1&utm_campaign=16 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Avis Budget Group, Inc. (NASDAQ:CAR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/avis-budget-lawsuit-submission-form?prid=151717&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151719&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your DoubleVerify Holdings, Inc. (NYSE:DV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/doubleverify-holdings-inc-lawsuit-submission-form-2?prid=151720&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Digimarc Corporation (NASDAQ:DMRC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/digimarc-corporation-lawsuit-submission-form-2?prid=151704&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=151705&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Red Cat Holdings, Inc. (NASDAQ:RCAT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/red-cat-holdings-inc-lawsuit-submission-form?prid=151706&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=151703&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=151718&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.

WAUKESHA, Wis. , June 5, 2025 /PRNewswire/ -- Generac Holdings Inc. (NYSE: GNRC), a leading global designer, manufacturer and provider of energy technology solutions and other power products, today announced the promotion of Jim Barnes to Executive Vice President – Global Supply Chain.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of nCino, Inc. ("nCino, Inc.") (NASDAQ:NCNO) concerning possible violations of federal securities laws. On April 1, 2025, nCino reported positive 4Q 2025 financial results but announced fiscal 2026 guidance that was below analysts' expectations.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations

RESTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vestis Corporation ("Vestis Corporation") (NYSE:VSTS) concerning possible violations of federal securities laws. On May 6, 2025, Vestis reported a significant drop in 2Q 2025 revenue results that missed analysts' expectations.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.